{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:31:12Z","timestamp":1764084672626,"version":"3.44.0"},"reference-count":28,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,6,11]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>Following non-elective orthopaedic surgery, a 61-year-old man with poorly controlled type 2 diabetes mellitus on empagliflozin developed high anion gap metabolic acidosis in the high-dependency unit. Metabolic acidosis persisted despite intravenous sodium bicarbonate, contributing to tachycardia and a run of non-sustained ventricular tachycardia. He was euglycaemic throughout hospital admission. Investigations revealed elevated urine and capillary ketones, and a diagnosis of sodium\u2013glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis was made. He was treated with an intravenous sliding scale insulin infusion and concurrent dextrose 5% with potassium chloride. Within 24 hours of treatment, his arterial pH, anion gap and serum bicarbonate levels normalised. After a further 12 hours, the intravenous insulin infusion was converted to a basal\/bolus regimen of subcutaneous insulin, and he was transferred to the general ward. He was discharged well on subcutaneous insulin 6 days postoperatively.<\/jats:p>","DOI":"10.1136\/bcr-2020-235953","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T13:02:34Z","timestamp":1629205354000},"page":"e235953","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Case of sodium\u2013glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis"],"prefix":"10.1136","volume":"14","author":[{"given":"Huei Li","family":"Yeoh","sequence":"first","affiliation":[{"name":"Pharmacy Department, Mount Elizabeth Novena Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Lee","sequence":"additional","affiliation":[{"name":"Mount Elizabeth Novena Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woei Jack","family":"Pan","sequence":"additional","affiliation":[{"name":"Mount Elizabeth Novena Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hean Yee","family":"Ong","sequence":"additional","affiliation":[{"name":"Mount Elizabeth Novena Hospital, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"2025082722025976000_14.8.e235953.1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS"},{"key":"2025082722025976000_14.8.e235953.2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","article-title":"Diabetic ketoacidosis","volume":"6","author":"Dhatariya","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025082722025976000_14.8.e235953.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-9032"},{"key":"2025082722025976000_14.8.e235953.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03246.x"},{"key":"2025082722025976000_14.8.e235953.5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pedi.12701","article-title":"ISPAD clinical practice consensus guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state","volume":"19 Suppl 27","author":"Wolfsdorf","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2025082722025976000_14.8.e235953.6","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"Sglt2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"2025082722025976000_14.8.e235953.7","unstructured":"FDA Drug Safety Communication 2015 . FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm?source=govdeli [Accessed 21 Jul 2018]."},{"key":"2025082722025976000_14.8.e235953.8","unstructured":"EMA confirms recommendations to minimize ketoacidosis risk with SGLT2 inhibitors for diabetes, 2016. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp%3Fcurl%3Dpages\/medicines\/human\/referrals\/SGLT2_inhibitors\/human_referral_prac_000052.jsp%26mid%3DWC0b01ac05805c516f [Accessed 21 Jul 2018]."},{"key":"2025082722025976000_14.8.e235953.9","unstructured":"Health Canada summary safety review 2016: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) \u2013 assessing the risk of the body producing high levels of acids in the blood (diabetic ketoacidosis). Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin.html [Accessed 21 Jul 2018]."},{"key":"2025082722025976000_14.8.e235953.10","unstructured":"Health Services Authority Singapore Product Safety Alerts 19 May 2016 . Sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of serious diabetic ketoacidosis (DKA). Available: http:\/\/www.hsa.gov.sg\/content\/hsa\/en\/Health_Products_Regulation\/Safety_Information_and_Product_Recalls\/Product_Safety_Alerts\/2016\/sodium-glucose-cotransporter2sglt2inhibitorsandriskofseriousdiab.html [Accessed 21 Jul 2018]."},{"key":"2025082722025976000_14.8.e235953.11","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"2025082722025976000_14.8.e235953.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"2025082722025976000_14.8.e235953.13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884"},{"key":"2025082722025976000_14.8.e235953.14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12630-017-1019-5","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting","volume":"65","author":"Peacock","year":"2018","journal-title":"Can J Anaesth"},{"key":"2025082722025976000_14.8.e235953.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"2025082722025976000_14.8.e235953.16","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"2025082722025976000_14.8.e235953.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"2025082722025976000_14.8.e235953.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.51"},{"key":"2025082722025976000_14.8.e235953.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021887"},{"key":"2025082722025976000_14.8.e235953.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.03.005"},{"key":"2025082722025976000_14.8.e235953.21","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(75)90004-9"},{"key":"2025082722025976000_14.8.e235953.22","first-page":"F257","article-title":"Renal reabsorption and utilization of hydroxybutyrate and acetoacetate in starved rats","volume":"251","author":"Barac-Nieto","year":"1986","journal-title":"Am J Physiol"},{"key":"2025082722025976000_14.8.e235953.23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14740338.2017.1361400","article-title":"Acid-base and electrolyte disorders associated with the use of antidiabetic drugs","volume":"16","author":"Filippatos","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2025082722025976000_14.8.e235953.24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia"},{"key":"2025082722025976000_14.8.e235953.25","unstructured":"Australian Diabetes Society Alert update 2020 . Periprocedural diabetic ketoacidosis (DKA) with SGLT2 inhibitor use. Available: https:\/\/diabetessociety.com.au\/documents\/ADS_DKA_SGLT2i_Alert_update_2020.pdf [Accessed 17 Nov 2020]."},{"key":"2025082722025976000_14.8.e235953.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.03.028"},{"key":"2025082722025976000_14.8.e235953.27","unstructured":"Australian Diabetes Society Alert 2018 . Severe euglycaemic ketoacidosis with SGLT2 inhibitor use in the perioperative period. Available: https:\/\/diabetessociety.com.au\/documents\/2018_ALERT-ADS_SGLT2i_PerioperativeKetoacidosis_v3__final2018_02_14.pdf [Accessed 21 Jul 2018]."},{"key":"2025082722025976000_14.8.e235953.28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12630-017-1018-6","article-title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery","volume":"65","author":"Lau","year":"2018","journal-title":"Can J Anaesth"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:03:09Z","timestamp":1756357389000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,17]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bcr-2020-235953"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235953","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}